Comparison between Ahmed glaucoma valve implant and Keiki Mehta body pressure glaucoma implant in neovascular glaucoma: 24-month results

GÜLMEZ SEVİM D., Ozer F., ERKILIÇ K., ŞENER H., Evereklioglu G., ÜNLÜ M.

INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, cilt.19, sa.7, ss.1308-1315, 2026 (SCI-Expanded, Scopus)

Özet

center dot AIM: To compare the 24-month clinical results of the Keiki Mehta body pressure (BP) glaucoma implants (KMI) versus the Ahmed glaucoma valve implants (AGVI; FP-7Model) in neovascular glaucoma (NVG). center dot METHODS: Patients with NVG and uncontrolled intraocular pressure (IOP) exceeding 21 mm Hg despite maximum-tolerated antiglaucoma medications were included in this retrospective study and treated with either KMI, or AGVI. Preoperative and postoperative IOP (at the 1d, 1, 3, 6, 12, and 24mo), number of glaucoma medications needed, success rate, postoperative complications, and visual acuity were evaluated. center dot RESULTS: The study enrolled 41 patients, comprising 19 (11 males) in the KMI group (mean age: 58.8 +/- 10.6y) and 22 (11 males) in the AGVI group (mean age: 60.2 +/- 16.8y). Preoperative IOP was similar between the groups (P=0.077). Postoperative IOP at the 1st day and 1st month were lower in the KMI group compared to the AGVI group (P=0.003 and P=0.001, respectively). No significant difference was found between the groups at other time points. In both groups, 1st day and 24th month values were lower than baseline values (all P<0.001). At the end of 24mo, the number of antiglaucoma agents required, the success rate and total complications rate were similar between the groups (P=0.444, P=0.843, P=0.233, respectively). center dot CONCLUSION: KMI may be an alternative to AGVI in the management of NVG. To the best of our knowledge, this study is the first to compare the results of AGVI versus KMI for the treatment of NVG.